Core Viewpoint - The article discusses the recent volatility in the stock price of Yaojie Ankang (药捷安康), highlighting its significant price fluctuations and the impact of clinical trial news on its market performance [5][6][9]. Stock Performance Summary - On September 16, Yaojie Ankang's stock price surged nearly 60% at the opening, reaching a peak of 679.50 HKD per share, with a market cap exceeding 260 billion HKD. However, it closed down 53.73% on the same day, ending at 192.0 HKD per share [5][6]. - Following this, on September 17, the stock rebounded, closing up 8.96% at 209.2 HKD per share, with a total market cap of 83.03 billion HKD. By September 18, the stock fell again by 12.43% to 183.2 HKD per share [5][6]. - Since its IPO on June 23, the stock price has increased by 1293.16% from the initial offering price of 13.15 HKD per share [5]. Clinical Trial Developments - The primary driver behind the stock's recent surge was the announcement of a clinical trial for its core product, Tiengoni (替恩戈替尼), which received clinical trial approval from the National Medical Products Administration of China [9][10]. - Tiengoni is a multi-target kinase inhibitor that shows potential in treating various cancers, including cholangiocarcinoma, prostate cancer, liver cancer, and breast cancer. The company expects to complete the registration phase II clinical trial for cholangiocarcinoma by the second half of 2025 [11][12]. Financial Performance and Future Outlook - Yaojie Ankang has reported significant losses, totaling approximately 1 billion CNY over the past three and a half years, with losses of 252 million CNY in 2022, 343 million CNY in 2023, and 123 million CNY in the first half of 2024 [13][15]. - The company has raised over 1.7 billion CNY through multiple financing rounds since its establishment in 2014, relying heavily on external funding to support its operations and R&D efforts [15]. - Despite the promising developments, the company is still in the registration clinical phase and has not yet commercialized any products, indicating a long road ahead before potential market entry [15].
暴涨1293%能稳住吗？药捷安康“闪崩”后又跌了